Literature DB >> 19003034

Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development.

Philippe-Alexandre Gilbert1, Lacrimioara Comanita, John Barrett, Andrew Peters, Marta Szabat, Grant McFadden, Gregory A Dekaban.   

Abstract

In light of the recent detection of BSE in North America and its endemic nature in other regions of the world, there is a real need to employ cell culture conditions that do not require any animal-derived material. Here we report the use of an ultra-low protein serum-free medium (VP-SFM, Invitrogen) for the amplification of poxviruses in primary chicken embryo fibroblasts (CEF). We compared the amplification of four different poxviruses (canarypox, modified Ankara Virus (MVA), vaccinia virus strain Copenhagen and myxoma strain Lausanne) in three different media: DMEM 10%, DMEM 2% and serum-free medium VP-SFM. VP-SFM is a serum-free, ultra-low protein medium containing no proteins or peptides of human or animal origin designed to support the replication of viruses and the production of recombinant proteins and monoclonal antibodies. Our results show that high titre poxvirus stocks can be prepared in VP-SFM equivalent to that prepared in serum containing medium.

Entities:  

Year:  2005        PMID: 19003034      PMCID: PMC3449719          DOI: 10.1007/s10616-005-3795-y

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  12 in total

1.  Live viral vectors: vaccinia virus.

Authors:  Caroline Staib; Gerd Sutter
Journal:  Methods Mol Med       Date:  2003

2.  Checking sources: the serum supply secret.

Authors:  J Hodgson
Journal:  Biotechnology (N Y)       Date:  1991-12

3.  Characterization of the antibody response to three different versions of the HTLV-I envelope protein expressed by recombinant vaccinia viruses: induction of neutralizing antibody.

Authors:  C M Ford; J Arp; T J Palker; E E King; G A Dekaban
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

4.  Advanced Granulation Technology (AGT(TM)). An alternate format for serum-free, chemically-defined and protein-free cell culture media.

Authors:  R Fike; B Dadey; R Hassett; R Radominski; D Jayme; D Cady
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

5.  Media formulation options and manufacturing process controls to safeguard against introduction of animal origin contaminants in animal cell culture.

Authors:  D W Jayme; S R Smith
Journal:  Cytotechnology       Date:  2000-07       Impact factor: 2.058

6.  Compact, synthetic, vaccinia virus early/late promoter for protein expression.

Authors:  S Chakrabarti; J R Sisler; B Moss
Journal:  Biotechniques       Date:  1997-12       Impact factor: 1.993

7.  [Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine].

Authors:  A Mayr
Journal:  Berl Munch Tierarztl Wochenschr       Date:  1999-09       Impact factor: 0.328

8.  Cultural and physiological factors affecting expression of recombinant proteins.

Authors:  J B Griffiths; A J Racher
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

9.  Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor.

Authors:  A Opgenorth; K Graham; N Nation; D Strayer; G McFadden
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

10.  Production of recombinant proteins in Chinese hamster ovary cells using a protein-free cell culture medium.

Authors:  M Zang; H Trautmann; C Gandor; F Messi; F Asselbergs; C Leist; A Fiechter; J Reiser
Journal:  Biotechnology (N Y)       Date:  1995-04
View more
  4 in total

1.  Introduction to animal cell culture technology-past, present and future.

Authors:  O-W Merten
Journal:  Cytotechnology       Date:  2006-08-03       Impact factor: 2.058

2.  Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.

Authors:  Joseph N Brewoo; Tim D Powell; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2010-07-12       Impact factor: 3.641

3.  Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Authors:  Joseph N Brewoo; Tim D Powell; Jeremy C Jones; Nancy A Gundlach; Ginger R Young; Haiyan Chu; Subash C Das; Charalambos D Partidos; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2013-02-01       Impact factor: 3.641

4.  An efficient method for generating poxvirus recombinants in the absence of selection.

Authors:  Amanda D Rice; Stacey A Gray; Yu Li; Inger Damon; Richard W Moyer
Journal:  Viruses       Date:  2011-03       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.